Business Context and Reporting Period
This Form 8-K is a current report filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on July 6, 2020. The filing addresses an administrative error discovered in previously filed Annual Reports on Form 10-K, including the report for the year ended December 31, 2019. The error involved incorrect filing, issued, and/or expiration dates for certain owned and licensed patents.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly informational regarding intellectual property data corrections and contains no financial performance data.
Material Changes
The material change reported is the correction of patent date information. The Company identified that prior filings contained erroneous dates for specific patents. A comprehensive table of corrected dates for 24 patents (covering technologies such as Nicotinamide Riboside and Pterostilbene) is provided in the filing.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or new risk factors. The primary contingency addressed is the rectification of the administrative error to ensure accurate public disclosure of the Company's intellectual property portfolio.
Investor Verification Checklist
- Verify the corrected filing, issued, and expiration dates for the 24 listed patents against the Company's intellectual property portfolio.
- Confirm that the corrected dates do not alter the Company's competitive moat or royalty obligations to licensors (e.g., Cornell University, Dartmouth College, Queen's University of Belfast).
- Review the amended Form 10-K for the year ended December 31, 2019, to ensure the corrections have been properly reflected in the official record.
- Note that the registrant is ChromaDex Corporation (Ticker: CDXC), not Niagen Bioscience, Inc.